Literature DB >> 16339897

Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes.

Gabrielle G M Pinkse1, Odette H M Tysma, Cees A M Bergen, Michel G D Kester, Ferry Ossendorp, Peter A van Veelen, Bart Keymeulen, Danny Pipeleers, Jan W Drijfhout, Bart O Roep.   

Abstract

Type 1 diabetes is a T cell-mediated autoimmune disease, and insulin is an important target of the autoimmune response associated with beta cell destruction. The mechanism of destruction is still unknown. Here, we provide evidence for CD8 T cell autoreactivity associated with recurrent autoimmunity and loss of beta cell function in type 1 diabetic islet transplant recipients. We first identified an insulin B chain peptide (insB10-18) with extraordinary binding affinity to HLA-A2(*0201) that is expressed by the majority of type 1 diabetes patients. We next demonstrated that this peptide is naturally processed by both constitutive and immuno proteasomes and translocated to the endoplasmic reticulum by the peptide transporter TAP1 to allow binding to HLA-A2 in the endoplasmic reticulum and cell surface presentation. Peripheral blood mononuclear cells from a healthy donor were primed in vitro with this peptide, and CD8 T cells were isolated that specifically recognize target cells expressing the insulin B chain peptide. HLA-A2(insB10-18) tetramer staining revealed a strong association between detection of autoreactive CD8 T cells and recurrent autoimmunity after islet transplantation and graft failure in type 1 diabetic patients. We demonstrate that CD8 T cell autoreactivity is associated with beta cell destruction in type 1 diabetes in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339897      PMCID: PMC1317949          DOI: 10.1073/pnas.0508621102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure.

Authors:  Bart O Roep
Journal:  Diabetologia       Date:  2003-03-22       Impact factor: 10.122

Review 2.  Endoplasmic reticulum stress and the development of diabetes: a review.

Authors:  Heather P Harding; David Ron
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

3.  Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice.

Authors:  Maki Nakayama; Norio Abiru; Hiroaki Moriyama; Naru Babaya; Edwin Liu; Dongmei Miao; Liping Yu; Dale R Wegmann; John C Hutton; John F Elliott; George S Eisenbarth
Journal:  Nature       Date:  2005-05-12       Impact factor: 49.962

4.  Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.

Authors:  Sally C Kent; Yahua Chen; Lisa Bregoli; Sue M Clemmings; Norma Sue Kenyon; Camillo Ricordi; Bernhard J Hering; David A Hafler
Journal:  Nature       Date:  2005-05-12       Impact factor: 49.962

5.  Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients.

Authors:  B O Roep; I Stobbe; G Duinkerken; J J van Rood; A Lernmark; B Keymeulen; D Pipeleers; F H Claas; R R de Vries
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

6.  Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

Authors:  Nathan R Martinez; Petra Augstein; Antonis K Moustakas; George K Papadopoulos; Silvia Gregori; Luciano Adorini; David C Jackson; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop.

Authors:  C F Verge; D Stenger; E Bonifacio; P G Colman; C Pilcher; P J Bingley; G S Eisenbarth
Journal:  Diabetes       Date:  1998-12       Impact factor: 9.461

8.  Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes.

Authors:  Constadina Panagiotopoulos; Huilian Qin; Rusung Tan; C Bruce Verchere
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

9.  Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice.

Authors:  Michele P Marron; Robert T Graser; Harold D Chapman; David V Serreze
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-02       Impact factor: 11.205

Review 10.  Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention.

Authors:  Roland S Liblau; F Susan Wong; Lennart T Mars; Pere Santamaria
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

View more
  123 in total

1.  IL-7Rαlow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus.

Authors:  Jung-Sik Kim; Bon-A Cho; Ji Hyun Sim; Kamini Shah; Connie M Woo; Eun Bong Lee; Dong-Sup Lee; Jae Seung Kang; Wang Jae Lee; Chung-Gyu Park; Joe Craft; Insoo Kang; Hang-Rae Kim
Journal:  Rheumatology (Oxford)       Date:  2012-06-01       Impact factor: 7.580

2.  Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire.

Authors:  Menno van Lummel; Peter A van Veelen; Arnaud Zaldumbide; Arnoud de Ru; George M C Janssen; Antonis K Moustakas; George K Papadopoulos; Jan W Drijfhout; Bart O Roep; Frits Koning
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

3.  The problems and promises of research into human immunology and autoimmune disease.

Authors:  Bart O Roep; Jane Buckner; Stephen Sawcer; Rene Toes; Frauke Zipp
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 4.  Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes.

Authors:  S I Mannering; F S Wong; I Durinovic-Belló; B Brooks-Worrell; T I Tree; C M Cilio; N C Schloot; R Mallone
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

Review 5.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

Review 6.  Targeting memory T cells in type 1 diabetes.

Authors:  Mario R Ehlers; Mark R Rigby
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

Review 7.  Viruses and cytotoxic T lymphocytes in type 1 diabetes.

Authors:  Ken T Coppieters; Matthias G von Herrath
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

8.  Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Authors:  Simi Ahmed; Karen Cerosaletti; Eddie James; S Alice Long; Stuart Mannering; Cate Speake; Maki Nakayama; Timothy Tree; Bart O Roep; Kevan C Herold; Todd M Brusko
Journal:  Diabetes       Date:  2019-07       Impact factor: 9.461

Review 9.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

Review 10.  Biomarkers in type 1 diabetes: application to the clinical trial setting.

Authors:  James E Tooley; Kevan C Herold
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-08       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.